Messerschmidt Addresses the Future of Cancer Vaccines in FiercePharma

Precision Oncology’s Gerry Messerschmidt, MD, talks with FiercePharma’s Eric Sagonowsky and predicts we’ll see licensed cancer vaccines in the next 2 to 3 years.

To read the complete article, please click here.


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.